Short Interest To Observe: Cerus Corporation (NASDAQ:CERS)’s Stock Is Sell After More Market Selling

November 29, 2016 - By Darrin Black   ·   0 Comments

Short Interest To Observe: Cerus Corporation (NASDAQ:CERS)'s Stock Is Sell After More Market Selling

The stock of Cerus Corporation (NASDAQ:CERS) registered an increase of 4.13% in short interest. CERS’s total short interest was 17.40 million shares in November as published by FINRA. Its up 4.13% from 16.71 million shares, reported previously. With 721,400 shares average volume, it will take short sellers 24 days to cover their CERS’s short positions. The short interest to Cerus Corporation’s float is 19.92%. The stock closed at $5.47 during the last session. It is down 15.19% since April 26, 2016 and is downtrending. It has underperformed by 20.45% the S&P500.

Cerus Corporation is a biomedical products company. The company has a market cap of $540.28 million. The Firm is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. It currently has negative earnings. The Firm operates through blood safety segment.

Insitutional Activity: The institutional sentiment decreased to 1.06 in Q2 2016. Its down 0.63, from 1.69 in 2016Q1. The ratio is negative, as 10 funds sold all Cerus Corporation shares owned while 26 reduced positions. 8 funds bought stakes while 53 increased positions. They now own 66.39 million shares or 1.07% more from 65.69 million shares in 2016Q1.
Deutsche Retail Bank Ag has invested 0.01% of its portfolio in Cerus Corporation (NASDAQ:CERS). First Midwest Comml Bank Trust Division holds 0.32% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 415,292 shares. Turner L P, a Pennsylvania-based fund reported 60,000 shares. Driehaus Cap Mgmt Ltd Liability holds 843,193 shares or 0.19% of its portfolio. Dekabank Deutsche Girozentrale holds 48,000 shares or 0% of its portfolio. Grp One Trading Lp holds 82,037 shares or 0.01% of its portfolio. Salzhauer Michael last reported 1.45% of its portfolio in the stock. Elm Ltd Liability has 20,000 shares for 0.12% of their US portfolio. Royal Commercial Bank Of Canada last reported 14,000 shares in the company. Teachers Advsr last reported 0% of its portfolio in the stock. Tiaa Cref Invest Mngmt Ltd Co, a New York-based fund reported 440,105 shares. Raub Brock Cap Mgmt Lp holds 0.05% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 29,399 shares. Blackrock Institutional Tru Co Na, a California-based fund reported 2.57 million shares. Blackrock Fund Advsrs accumulated 0.01% or 3.95 million shares. Moreover, Swiss Natl Bank has 0% invested in Cerus Corporation (NASDAQ:CERS) for 168,900 shares.

Insider Transactions: Since August 22, 2016, the stock had 0 insider purchases, and 1 insider sale for $116,612 net activity. Green Kevin Dennis had sold 17,150 shares worth $116,612.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Out of 2 analysts covering Cerus (NASDAQ:CERS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cerus has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, December 17 by Wedbush. BTIG Research maintained it with “Buy” rating and $8 target price in Wednesday, August 19 report. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Tuesday, August 11 by Zacks.

CERS Company Profile

Cerus Corporation, incorporated on July 31, 1996, is a biomedical products company. The Firm is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Firm operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

More important recent Cerus Corporation (NASDAQ:CERS) news were published by: Fool.com which released: “Why Cerus Corporation is Soaring Today” on November 04, 2016, also Fool.com published article titled: “Cerus Corporation is Surging Today. Here’s Why.”, Fool.com published: “The Probable Reason Behind Cerus Corp’s 11.2% Drop in May” on June 09, 2016. More interesting news about Cerus Corporation (NASDAQ:CERS) was released by: Businesswire.com and their article: “Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer” with publication date: August 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>